Free Hospital EMR and EHR Newsletter Want to receive the latest news on EMR, Meaningful Use, ARRA and Healthcare IT sent straight to your email? Join thousands of healthcare pros who subscribe to Hospital EMR and EHR for FREE!

Lumeon secures $28M To Accelerate US Expansion

Posted on December 7, 2018 I Written By

Colin Hung is the co-founder of the #hcldr (healthcare leadership) tweetchat one of the most popular and active healthcare social media communities on Twitter. Colin speaks, tweets and blogs regularly about healthcare, technology, marketing and leadership. He is currently an independent marketing consultant working with leading healthIT companies. Colin is a member of #TheWalkingGallery. His Twitter handle is: @Colin_Hung.

Lumeon, makers of a care pathway management (CPM) platform that helps patients receive the appropriate follow-up care, recently announced $28M in new funding. The investment was led by Life Sciences Partners (LSP) one of Europe’s largest healthcare investment firms.

The company was part of the third cohort of startups that came through the Cedars-Sinai Accelerator in the fall of 2017. At the time Lumeon already had 1,800 healthcare sites live on their platform in the United Kingdom, where they maintain their European headquarters. The company’s US headquarters is in Boston.

Lumeon’s platform automates many parts of the patient journey, saving time, eliminating gaps and reducing frustration for both staff as well as patients.

The $28M raised will help accelerate Lumeon’s expansion in the US healthcare market. In an exclusive email interview with Healthcare Scene, Robbie Hughes, Founder and CEO for Lumeon, explained how the funds would be used.

“Our priority is hiring the best people to allow us to keep delivering for our customers. We’ll focus initially on building out our deployment and customer support teams to accelerate new customer implementations. The funding will allow us to grow our business rapidly and take advantage of this critical moment in the healthcare market.”

The company anticipates hiring 25 new staff to support their US market expansion.

When asked why Lumeon is well positioned to succeed in a crowed market, Hughes pointed to the company’s strong user base in Europe and clear ROI.

“We have proven our solution at scale in a market with significant cost constraints, and these initiatives have resulted in a series of key insights that help us stand out from competitors. Our customers see the immediate reduction in costs brought by automating manual tasks. They also see a revenue increase from attracting new patients.”

Lumeon was recently named a Gartner Cool Vendor for 2018.

More information about the funding announcement can be found on the company’s website.

Apple Trials Tech Offering Patient Access To Their Health Records

Posted on January 29, 2018 I Written By

Anne Zieger is veteran healthcare branding and communications expert with more than 25 years of industry experience. and her commentaries have appeared in dozens of international business publications, including Forbes, Business Week and Information Week. She has also worked extensively healthcare and health IT organizations, including several Fortune 500 companies. She can be reached at @ziegerhealth or

In recent times, tech giants have been falling over themselves in a race to offer consumers the best access to their health data, including even dark horses like Amazon. And it’s little wonder – it’s become increasingly obvious that he who controls patient health data access controls a critical sector of the entire healthcare industry.

The most recent stake in the ground comes from Apple, whose latest update to its Health app allows customers to see their medical records on their iPhone. The Health Records section of the Health app, which comes with the release of the iOS 11.3 beta, collects FHIR-based records from multiple sources and makes them available through its Health Records section.

The patient data display will pull together patient data from various healthcare organizations into a single view. The data will include lists of allergies, conditions and medications taken, immunizations records, lab results on procedures and vital sign information. When providers published new information, iPhone users will be notified.

To conduct its Health Records beta test, Apple has partnered with a number of high-profile health systems and hospitals, including Johns Hopkins Medicine; Cedars-Sinai; Penn Medicine; Geisinger Health System; UC San Diego Health; UNC Health Care; Rush University Medical Center; Dignity Health; Ochsner Health System; MedStar Health and OhioHealth.

As part of its launch, Apple told the New York Times that unless consumers specifically choose to share it with the company, it will never see the data, which will be encrypted and stored locally on the iPhone.  A recent (if unscientific) poll suggests that consumers trust Apple with their health data more than other top tech vendors, so this reassurance may be enough to ease their fears.

But security is hardly Apple’s biggest concern. How does the tech colossus expect to profit from its health data investments?  When I break the issues down, it looks like this:

  • Unlike hospitals and clinics, which can expect medium- to long-term ROI when patients manage their health better, Apple doesn’t deliver care.
  • Apple might want to sell anonymized aggregated patient data, but as far as I know, the company would still have to get patient permission, and that would be an administrative and legal nightmare.
  • If Apple or its competitors have some vision of selling access to the patient, good luck with that. Providers have a hard time attracting and keeping patients with nifty technology even if those patients live in their backyard.

While I could be missing something major, from what I see, Apple, Google, Samsung, Amazon and the rest are engaging in a series of preemptive patient data land grabs. My sense is that none of them know exactly what to do with this data, they’ll be damned if they’re going to let their competitors get there first.

That said, many in the industry are suggesting that this move is just another effort by Apple to sell more iPhones. The question I ask is how valuable will the information be to the patients? Certainly the beta hospitals and health systems are large and have a lot of data, but how is this going to scale down to the smaller providers? If you don’t have these smaller providers, then you’re going to be missing some of the most important health data.